Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site

Abstract excerpt

BACKGROUND: Liquid biopsies (LB) are used increasingly to detect actionable mutations in patients newly diagnosed with advanced non-small cell lung cancer (aNSCLC), though tissue biopsies (TB) still remain the gold standard. The value of systematically combining LB and TB next-generation sequencing (NGS) for genomic profiling in these patients remains controversial. METHODS: This single-centre retrospective study...

Topics

Join the communities discussing this publication.

• Cancer Genomics and Diagnostics
• Lung Cancer Diagnosis and Treatment
• Lung Cancer Treatments and Mutations